These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38029012)

  • 1. Proton beam stereotactic body radiotherapy and hypofractionated therapy with pencil beam scanning is safe and effective for advanced hepatocellular carcinoma and intrahepatic cholangiocarcinoma: A single center experience.
    Yang AH; Urrunaga NH; Siddiqui O; Wu A; Schliep M; Mossahebi S; Shetty K; Regine WF; Molitoris JK; Lominadze Z
    J Radiosurg SBRT; 2023; 9(1):43-52. PubMed ID: 38029012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypofractionated proton beam radiotherapy in patients with unresectable liver tumors: multi-institutional prospective results from the Proton Collaborative Group.
    Parzen JS; Hartsell W; Chang J; Apisarnthanarax S; Molitoris J; Durci M; Tsai H; Urbanic J; Ashman J; Vargas C; Stevens C; Kabolizadeh P
    Radiat Oncol; 2020 Nov; 15(1):255. PubMed ID: 33148296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proton beam therapy versus stereotactic body radiotherapy for hepatocellular carcinoma: practice patterns, outcomes, and the effect of biologically effective dose escalation.
    Hasan S; Abel S; Verma V; Webster P; Arscott WT; Wegner RE; Kirichenko A; Simone CB
    J Gastrointest Oncol; 2019 Oct; 10(5):999-1009. PubMed ID: 31602338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proton Beam Therapy for Treatment-Naïve Hepatocellular Carcinoma and Prognostic Significance of Albumin-Bilirubin (ALBI) Grade.
    Kim TH; Kim BH; Park JW; Cho YR; Koh YH; Chun JW; Oh ES; Lee DY; Lee SU; Suh YG; Woo SM; Moon SH; Kim SS; Lee WJ
    Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of hepatic toxicity in small liver tumors after photon or proton therapy based on factors predicting the benefits of proton.
    Uchinami Y; Katoh N; Abo D; Morita R; Taguchi H; Fujita Y; Kanehira T; Suzuki R; Miyamoto N; Takao S; Matsuura T; Sho T; Ogawa K; Orimo T; Kakisaka T; Kobashi K; Aoyama H
    Br J Radiol; 2023 Mar; 96(1144):20220720. PubMed ID: 36633335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II trial of hypofractionated high-dose proton beam therapy for unresectable liver metastases.
    Kim K; Yu JI; Park HC; Yoo GS; Lim DH; Noh JM; Jeong WK
    Radiother Oncol; 2022 Nov; 176():9-16. PubMed ID: 36113779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline Albumin-Bilirubin (ALBI) Score in Western Patients With Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy (SBRT).
    Murray LJ; Sykes J; Brierley J; Kim JJ; Wong RKS; Ringash J; Craig T; Velec M; Lindsay P; Knox JJ; Dawson LA
    Int J Radiat Oncol Biol Phys; 2018 Jul; 101(4):900-909. PubMed ID: 29976502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of single-energy proton pencil beam scanning Bragg peak for intensity-modulated proton therapy FLASH treatment planning in liver-hypofractionated radiation therapy.
    Wei S; Lin H; Shi C; Xiong W; Chen CC; Huang S; Press RH; Hasan S; Chhabra AM; Choi JI; Simone CB; Kang M
    Med Phys; 2022 Oct; 49(10):6560-6574. PubMed ID: 35929404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Efficacy of Hypofractionated Proton Beam Therapy for Intrahepatic Cholangiocarcinoma.
    Kim TH; Woo SM; Lee WJ; Chun JW; Cho YR; Kim BH; Koh YH; Kim SS; Oh ES; Lee DY; Lee SU; Suh YG; Moon SH; Park JW
    Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proton beam therapy outcomes for localized unresectable hepatocellular carcinoma.
    Chadha AS; Gunther JR; Hsieh CE; Aliru M; Mahadevan LS; Venkatesulu BP; Crane CH; Das P; Herman JM; Koay EJ; Taniguchi C; Holliday EB; Minsky BD; Suh Y; Park P; Sawakuchi G; Beddar S; Odisio BC; Gupta S; Loyer E; Kaur H; Raghav K; Javle MM; Kaseb AO; Krishnan S
    Radiother Oncol; 2019 Apr; 133():54-61. PubMed ID: 30935582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of clinical outcomes between passive scattering versus pencil-beam scanning proton beam therapy for hepatocellular carcinoma.
    Yoo GS; Yu JI; Cho S; Jung SH; Han Y; Park S; Oh Y; Lee B; Park HC; Lim DH; Choi MS; Won H
    Radiother Oncol; 2020 May; 146():187-193. PubMed ID: 32179362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.
    Hong TS; Wo JY; Yeap BY; Ben-Josef E; McDonnell EI; Blaszkowsky LS; Kwak EL; Allen JN; Clark JW; Goyal L; Murphy JE; Javle MM; Wolfgang JA; Drapek LC; Arellano RS; Mamon HJ; Mullen JT; Yoon SS; Tanabe KK; Ferrone CR; Ryan DP; DeLaney TF; Crane CH; Zhu AX
    J Clin Oncol; 2016 Feb; 34(5):460-8. PubMed ID: 26668346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proton beam radiotherapy combined with anti-PD1/PDL1 immune checkpoint inhibitors for advanced hepatocellular carcinoma.
    Su CW; Hou MM; Huang PW; Chou YC; Huang BS; Tseng JH; Hsu CW; Chang TC; Lin SM; Lin CC
    Am J Cancer Res; 2022; 12(4):1606-1620. PubMed ID: 35530291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    Tse RV; Hawkins M; Lockwood G; Kim JJ; Cummings B; Knox J; Sherman M; Dawson LA
    J Clin Oncol; 2008 Feb; 26(4):657-64. PubMed ID: 18172187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial clinical outcomes of proton beam radiotherapy for hepatocellular carcinoma.
    Yu JI; Yoo GS; Cho S; Jung SH; Han Y; Park S; Lee B; Kang W; Sinn DH; Paik YH; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Park HC
    Radiat Oncol J; 2018 Mar; 36(1):25-34. PubMed ID: 29580046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chest wall toxicity after hypofractionated proton beam therapy for liver malignancies.
    Yeung R; Bowen SR; Chapman TR; MacLennan GT; Apisarnthanarax S
    Pract Radiat Oncol; 2018; 8(4):287-293. PubMed ID: 29452863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longer Survival and Preserved Liver Function after Proton Beam Therapy for Patients with Unresectable Hepatocellular Carcinoma.
    Nosaka T; Matsuda H; Sugata R; Akazawa Y; Takahashi K; Naito T; Ohtani M; Kinoshita K; Tsujikawa T; Sato Y; Maeda Y; Tamamura H; Nakamoto Y
    Curr Oncol; 2023 Mar; 30(4):3915-3926. PubMed ID: 37185409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Efficacy of Accelerated Hypofractionation and Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma Patients With Varying Degrees of Hepatic Impairment.
    Nabavizadeh N; Waller JG; Fain R; Chen Y; Degnin CR; Elliott DA; Mullins BT; Patel IA; Dyer BA; Fakhoury K; Naugler WE; Farsad K; Tanyi JA; Fuss M; Thomas CR; Hung AY
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):577-585. PubMed ID: 29413273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Toxicity of Stereotactic Body Radiotherapy for Early to Advanced Stage Hepatocellular Carcinoma - Initial Experience From an Australian Liver Cancer Service.
    Liu HY; Lee Y; McLean K; Leggett D; Hodgkinson P; Fawcett J; Mott R; Stuart K; Pryor D
    Clin Oncol (R Coll Radiol); 2020 Oct; 32(10):e194-e202. PubMed ID: 32345457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of hepatic function decline after stereotactic body radiation therapy for primary liver cancer.
    Toesca DAS; Osmundson EC; von Eyben R; Shaffer JL; Koong AC; Chang DT
    Pract Radiat Oncol; 2017; 7(3):173-182. PubMed ID: 28343896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.